A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard of care (SOC) treatment following hospitalization for a COPD exacerbation

Chronic obstructive pulmonary disease (COPD)

Time to first all-cause event (all-cause event may include non-elective hospital readmission, Emergency Department (ED)/urgent care visit, or death), Number of moderate or severe COPD exacerbations

Time to first COPD-related event (COPD-related event may include non-elective hospital readmission, Emergency Department (ED)/urgent care visit, or death), Time to first moderate and/or severe COPD exacerbation, Number of all-cause non-elective hospital readmissions, Number of ED visits, Number of COPD-related hospital readmissions, Number of COPD-related ED visits, Number of all-cause deaths, Number of COPD-related deaths, Occurrence of all-cause non-elective hospital readmissions, ED visits, or deaths, Occurrence of COPD-related hospital readmissions, ED visits, or deaths, Change from baseline in Chronic Airways Assessment Test (CAAT) score (CAAT is a PRO measure that assesses the impact of lung disease on a person's life using an 8-item questionnaire with a 40-point scale with higher scores indicating worse disease), Change from baseline in EXAcerbation of Chronic pulmonary disease Tool (EXACT) questionnaire score (EXACT is a patient-reported daily diary that captures respiratory symptoms in COPD using a 14-item questionnaire with a 0 to 100-point scale with higher scores indicating worse disease symptoms), Occurrence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

No related papers found yet.